147 related articles for article (PubMed ID: 1573642)
1. Bis(maltolato)oxovanadium(IV) is a potent insulin mimic.
McNeill JH; Yuen VG; Hoveyda HR; Orvig C
J Med Chem; 1992 Apr; 35(8):1489-91. PubMed ID: 1573642
[No Abstract] [Full Text] [Related]
2. Effect of chronic treatment with Bis(maltolato)oxovanadium (IV) in rat model of non-insulin-dependent-diabetes.
Shinde UA; Mehta AA; Goyal RK
Indian J Exp Biol; 2001 Sep; 39(9):864-70. PubMed ID: 11831366
[TBL] [Abstract][Full Text] [Related]
3. [Synthesis and hypoglycemic activity of bis(L-malato)oxovanadium(IV)].
Gorodetskiĭ VK; Tochilkin AI; Beliaeva NF; Kovel'man IR; Korovkin BF
Biomed Khim; 2011; 57(1):133-7. PubMed ID: 21516785
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, characterization and anti-diabetic therapeutic potential of a new benzyl acid-derivatized kojic acid vanadyl complex.
Wei YB; Yang XD
Biometals; 2012 Dec; 25(6):1261-8. PubMed ID: 23015214
[TBL] [Abstract][Full Text] [Related]
5. Bis(maltolato)oxovanadium(IV) attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats.
Bhanot S; Bryer-Ash M; Cheung A; McNeill JH
Diabetes; 1994 Jul; 43(7):857-61. PubMed ID: 8013747
[TBL] [Abstract][Full Text] [Related]
6. Syntheses of vanadyl and zinc(II) complexes of 1-hydroxy-4,5,6-substituted 2(1H)-pyrimidinones and their insulin-mimetic activities.
Yamaguchi M; Wakasugi K; Saito R; Adachi Y; Yoshikawa Y; Sakurai H; Katoh A
J Inorg Biochem; 2006 Feb; 100(2):260-9. PubMed ID: 16387366
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms by which bis(maltolato)oxovanadium(IV) normalizes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase expression in streptozotocin-diabetic rats in vivo.
Marzban L; Rahimian R; Brownsey RW; McNeill JH
Endocrinology; 2002 Dec; 143(12):4636-45. PubMed ID: 12446591
[TBL] [Abstract][Full Text] [Related]
8. Bis(allixinato)oxovanadium(IV) complex is a potent antidiabetic agent: studies on structure-activity relationship for a series of hydroxypyrone-vanadium complexes.
Adachi Y; Yoshida J; Kodera Y; Katoh A; Takada J; Sakurai H
J Med Chem; 2006 Jun; 49(11):3251-6. PubMed ID: 16722643
[TBL] [Abstract][Full Text] [Related]
9. Bis(6-ethylpicolinato)oxovanadium(IV) complex with normoglycemic activity in KK-A(y) mice.
Sasagawa T; Yoshikawa Y; Kawabe K; Sakurai H; Kojima Y
J Inorg Biochem; 2002 Jan; 88(1):108-12. PubMed ID: 11750032
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, structural properties and insulin-enhancing potential of bis(quercetinato)oxovanadium(IV) conjugate.
Shukla R; Barve V; Padhye S; Bhonde R
Bioorg Med Chem Lett; 2004 Oct; 14(19):4961-5. PubMed ID: 15341960
[TBL] [Abstract][Full Text] [Related]
11. A new halogenated antidiabetic vanadyl complex, bis(5-iodopicolinato)oxovanadium(IV): in vitro and in vivo insulinomimetic evaluations and metallokinetic analysis.
Takino T; Yasui H; Yoshitake A; Hamajima Y; Matsushita R; Takada J; Sakurai H
J Biol Inorg Chem; 2001 Feb; 6(2):133-42. PubMed ID: 11293406
[TBL] [Abstract][Full Text] [Related]
12. Insulin-enhancing vanadium(III) complexes.
Melchior M; Rettig SJ; Liboiron BD; Thompson KH; Yuen VG; McNeill JH; Orvig C
Inorg Chem; 2001 Aug; 40(18):4686-90. PubMed ID: 11511216
[TBL] [Abstract][Full Text] [Related]
13. A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato)oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats.
Winter CL; Lange JS; Davis MG; Gerwe GS; Downs TR; Peters KG; Kasibhatla B
Exp Biol Med (Maywood); 2005 Mar; 230(3):207-16. PubMed ID: 15734724
[TBL] [Abstract][Full Text] [Related]
14. Acute and chronic response to vanadium following two methods of streptozotocin-diabetes induction.
Yao J; Battell ML; McNeill JH
Can J Physiol Pharmacol; 1997 Feb; 75(2):83-90. PubMed ID: 9114928
[TBL] [Abstract][Full Text] [Related]
15. Vanadium treatment of type 2 diabetes: a view to the future.
Thompson KH; Lichter J; LeBel C; Scaife MC; McNeill JH; Orvig C
J Inorg Biochem; 2009 Apr; 103(4):554-8. PubMed ID: 19162329
[TBL] [Abstract][Full Text] [Related]
16. The influence of BMOV [bis(maltolato)oxovanadium(IV)] on biochemical and morphological alterations characteristic for streptozotocin-diabetic rat liver Golgi complexes.
Dabroś W; Dziga D; Kordowiak AM
Pol J Pathol; 2002; 53(4):205-13. PubMed ID: 12597338
[TBL] [Abstract][Full Text] [Related]
17. [Hypoglycemic effects of bis(maltolato)oxovanadium administered by different routes upon diabetic rats].
Zhong XY; Zhang H; Zhang X; Lv WL; Zhang Q
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Jun; 36(3):313-8. PubMed ID: 15205708
[TBL] [Abstract][Full Text] [Related]
18. Insulinomimetic bis(maltolato)zinc(II) complex: blood glucose normalizing effect in KK-A(y) mice with type 2 diabetes mellitus.
Yoshikawa Y; Ueda E; Miyake H; Sakurai H; Kojima Y
Biochem Biophys Res Commun; 2001 Mar; 281(5):1190-3. PubMed ID: 11243860
[TBL] [Abstract][Full Text] [Related]
19. The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
Zhang SQ; Zhong XY; Chen GH; Lu WL; Zhang Q
J Pharm Pharmacol; 2008 Jan; 60(1):99-105. PubMed ID: 18088510
[TBL] [Abstract][Full Text] [Related]
20. Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes.
Thompson KH; Chiles J; Yuen VG; Tse J; McNeill JH; Orvig C
J Inorg Biochem; 2004 May; 98(5):683-90. PubMed ID: 15134913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
